Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18356083
Yasuda T, et al. (2008) Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 28, 499-508 18356083
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S133-p - CREB (mouse)
Modsite: EILSRRPsYRKILND SwissProt Entrez-Gene
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
U0126 anti-IgB inhibit treatment-induced increase

S384-p - ELK1 (mouse)
Modsite: IHFWSTLsPIAPRSP SwissProt Entrez-Gene
Orthologous residues
ELK1 (human): S383‑p, ELK1 (mouse): S384‑p, ELK1 (rat): S382‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
U0126 anti-IgB inhibit treatment-induced increase

S390-p - ELK1 (mouse)
Modsite: LSPIAPRsPAKLSFQ SwissProt Entrez-Gene
Orthologous residues
ELK1 (human): S389‑p, ELK1 (mouse): S390‑p, ELK1 (rat): S388‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse

S359-p - ELK3 (mouse)
Modsite: IHFWSSLsPVAPLSP SwissProt Entrez-Gene
Orthologous residues
ELK3 (human): S357‑p, ELK3 (mouse): S359‑p, ELK3 (rat): S358‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse

S365-p - ELK3 (mouse)
Modsite: LSPVAPLsPARLQGP SwissProt Entrez-Gene
Orthologous residues
ELK3 (human): S363‑p, ELK3 (mouse): S365‑p, ELK3 (rat): S364‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse

S380-p - ELK4 (mouse)
Modsite: IHFWSTLsPFAPLSP SwissProt Entrez-Gene
Orthologous residues
ELK4 (human): S381‑p, ELK4 (mouse): S380‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse

S386-p - ELK4 (mouse)
Modsite: LSPFAPLsPARLQGA SwissProt Entrez-Gene
Orthologous residues
ELK4 (human): S387‑p, ELK4 (mouse): S386‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse

T203-p - ERK1 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
anti-IgB Syk (mouse), ZAP70 (mouse) inhibit treatment-induced increase homozygous null
U0126 anti-IgB inhibit treatment-induced increase

Y205-p - ERK1 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
anti-IgB Syk (mouse), ZAP70 (mouse) inhibit treatment-induced increase homozygous null
U0126 anti-IgB inhibit treatment-induced increase

T183-p - ERK2 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
anti-IgB Syk (mouse), ZAP70 (mouse) inhibit treatment-induced increase homozygous null
U0126 anti-IgB inhibit treatment-induced increase

Y185-p - ERK2 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
anti-IgB Syk (mouse), ZAP70 (mouse) inhibit treatment-induced increase homozygous null
U0126 anti-IgB inhibit treatment-induced increase

T38-p - Ets-1 (mouse)
Modsite: CADVPLLtPSSKEMM SwissProt Entrez-Gene
Orthologous residues
Ets‑1 (human): T38‑p, Ets‑1 iso3 (human): T82‑p, Ets‑1 (mouse): T38‑p, Ets‑1 (rat): T38‑p, Ets‑1 (chicken): T38‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'B lymphocyte, precursor', B lymphocyte
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgB increase
U0126 anti-IgB inhibit treatment-induced increase